期刊文献+

人乳头瘤病毒感染的预防和治疗进展 被引量:3

Progress in the treatment of human papillomavirus infection
原文传递
导出
摘要 人乳头瘤病毒是一种环状双链DNA病毒。部分亚型可特异性地感染肛门生殖器皮肤和黏膜,导致生殖器疣和鳞状上皮内皮损等良恶性病变。宫颈持续的高危型人乳头瘤病毒感染是宫颈癌发生的必要条件。目前可用于治疗人乳头瘤病毒感染的方法主要有预防性疫苗、杀微生物剂、局部免疫调节剂、治疗性疫苗等。概述近年来针对人乳头瘤病毒的治疗进展。 Human papillomavirus (HPV) is a double-stranded DNA virus. Some HPV subtypes can specifically infect the skin and mucous membranes of the anogenital region, and induce a spectrum of epithelial proliferative diseases ranging from benign warts to intraepithelial neoplasms. It is now recognized that persistent cervical infection with high risk HPV subtypes is a prerequisite for the occurrence of cervical cancer. The treatment of HPV infection mainly includes prophylactic vaccines, microbicides, topical immunomodulators, therapeutic vaccines, etc. This paper presents recent progress in the treatment of HPV infection.
作者 米霞 郑和义
出处 《国际皮肤性病学杂志》 2012年第1期20-23,共4页 International Journal of Dermatology and Venereology
关键词 人乳头瘤病毒 感染 治疗 Human papillomavirus Infection Therapy
  • 相关文献

参考文献29

  • 1Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1999, 189 ( 1 ): 12-19.
  • 2Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol, 2002, 55 (4): 244-265.
  • 3Bosch FX, de Sanjose S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers, 2007, 23(4): 213-227.
  • 4Ochi H, Kondo K, Matsumoto K, et al. Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade eervieal intraepithelial neoplasia. Clin Vaeeine Immunol, 2008, 15 (10): 1536-1540.
  • 5Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med, 2002, 347 (21): 1645-1651.
  • 6Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, 2005, 6(5): 271-278.
  • 7Ault KA, Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet, 2007, 369(9576): 1861-1868.
  • 8Pomfret TC, Gagnon JM Jr, Gilchrist AT. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. J Clin Pharm Ther, 2011, 36( 1 ): 1-9.
  • 9Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet, 2006, 367(9518): 1247-1255.
  • 10Johnson KM, Kines RC, Roberts JN, et al. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol, 2009, 83 (5): 2067-2074.

同被引文献36

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部